Abstract
Enhanced therapeutic efficacy for glioblastoma immunotherapy with a new-generation oncolytic herpes simplex virus armed with anti-PD-1 antibody and IL-12
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have